Chugai obtained MHLW approval for the combination of mosunetuzumab (Lunsumio) subcutaneous and polatuzumab vedotin (Polivy) IV for relapsed or refractory large B‑cell lymphoma in patients not eligible for autologous hematopoietic ...
- Always free
- Visual (Beta)
-
Ssessments
- DailySSESSMENTS
- WeeklySSESSMENTS
- MonthlySSESSMENTS
- QuarterlySSESSMENTS
- NewsSSESSMENTS
- TalkSSESSMENTS
- PlantsSSESSMENTS
- AnalysisSSESSMENTS
- StatsSSESSMENTS
- PriceSSESSMENTS
- RumourSSESSMENTS
- InventorySSESSMENTS
- CustomerSSESSMENTS
- Illustrated SSESSMENTS
- One Liner Robert's Report
- GradeBasedPriceIndexSSESSMENTS
- Markets
- Commodities
